C. M. Español

Brief Report: Impact of COVID-19 on Cabotegravir Plus Rilpivirine Long-Acting Dosing Across 6 Ongoing Global Phase IIb and III Clinical Trials

C. Harrington, P. Patel, P. Benn, 2022, Journal of acquired immune deficiency syndromes.

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.

Kimberly Smith, H. Crauwels, E. Overton, 2021, The lancet. HIV.

Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study

S. Swindells, Kimberly Smith, H. Crauwels, 2023, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.